Literature DB >> 2579622

Reprioritization of hepatic plasma protein release in trauma and sepsis.

G Sganga, J H Siegel, G Brown, B Coleman, C E Wiles, H Belzberg, S Wedel, R Placko.   

Abstract

We studied the temporal pattern of seven hepatic synthesized plasma proteins in 26 severely injured patients beginning in the immediate posttrauma period. Clinical sepsis developed in ten patients between three and eight days after injury, and 16 patients had nonseptic courses. In the initial five days after injury, except for albumin, all acute-phase protein levels rose. However, if sepsis developed, C-reactive protein, fibrinogen, ceruloplasmin, and alpha 1-antitrypsin levels continued to be elevated after the initial five posttrauma days, while transferrin, albumin, and alpha 2-macroglobulin levels fell. This differential response became more extreme as sepsis progressed. Covariance analysis of the regression of the five true acute-phase hepatic proteins on C-reactive protein showed that, when sepsis occurred after major traumatic injury, the C-reactive protein rise was associated with a significant reprioritization of hepatic acute-phase plasma protein release. This reprioritization response seems to be both a predictor of sepsis as well as a measure of the adequacy of the host response to trauma and sepsis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579622     DOI: 10.1001/archsurg.1985.01390260051008

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

1.  Clinical outcome of seriously ill surgical patients with intra-abdominal infection depends on both physiologic (APACHE II score) and immunologic (DTH score) alterations.

Authors:  D Poenaru; N V Christou
Journal:  Ann Surg       Date:  1991-02       Impact factor: 12.969

2.  Predicting mortality based on body composition analysis.

Authors:  J M Tellado; J L Garcia-Sabrido; J A Hanley; H M Shizgal; N V Christou
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

3.  Hepatic dysfunction during bacterial sepsis.

Authors:  A E Gimson
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

4.  Gut mucosal nutritional support--enteral nutrition as primary therapy after multiple system trauma.

Authors:  K A Kudsk
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

5.  Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy.

Authors:  H F Starnes; R S Warren; M F Brennan
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

6.  Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy.

Authors:  Aoife M Ryan; Aine Hearty; Ruth S Prichard; Aileen Cunningham; Suzanne P Rowley; John V Reynolds
Journal:  J Gastrointest Surg       Date:  2007-10       Impact factor: 3.452

7.  Pharmacokinetics and disposition of monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic XueBiJing injection in human subjects and rats.

Authors:  Chen Cheng; Jia-zhen Lin; Li Li; Jun-ling Yang; Wei-wei Jia; Yu-hong Huang; Fei-fei Du; Feng-qing Wang; Mei-juan Li; Yan-fen Li; Fang Xu; Na-ting Zhang; Olajide E Olaleye; Yan Sun; Jian Li; Chang-hai Sun; Gui-ping Zhang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

8.  Survival from sepsis. The significance of altered protein metabolism regulated by proteolysis inducing factor, the circulating cleavage product of interleukin-1.

Authors:  G H Clowes; E Hirsch; B C George; L M Bigatello; J E Mazuski; C A Villee
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

9.  Inhibited muscle amino acid uptake in sepsis.

Authors:  P O Hasselgren; J H James; J E Fischer
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

Review 10.  A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury.

Authors:  Michael C Powanda; Elizabeth D Moyer
Journal:  Inflammopharmacology       Date:  2021-05-21       Impact factor: 4.473

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.